Michael Barbella, Managing Editor09.17.22
New products and new hires generated new pageview highs on ODT's website this past week.
Stryker Corp. led digital clicks by launching its Pulse Intelligent Delivery Platfom, a a full-circle product and fulfillment offering optimized for high volume foot and ankle procedures in the ambulatory surgery center (ASC) setting. The company will debut the platform at this year’s American Orthopaedic Foot & Ankle Society Annual Meeting (AOFAS). The Pulse Intelligent Delivery Platform provides an integrated product configuration and delivery offering for foot and ankle surgery within the ASC setting of care through a suite of surgery-ready forefoot products designed to reduce clutter in the operating room as well as provide ease of use, sterilization processing cost savings, and sustainability; and radio frequency identification technology that monitors ASC inventory and triggers replenishment orders automatically.
Conformis followed close behind in traffic generation with the FDA 510(k) clearance of its Actera hip system, which adds a tri-taper femoral stem design to the company’s hip portfolio. Its design objective is to facilitate a minimally invasive approach similar to direct anterior, with easier femur access, less injury to muscles, and fewer potential nerve interactions.
Nanofuse Biologics and Lima Corporate, meanwhile, attracted cybervisitors with their respective personnel news. Board-certified orthopedic spine surgeon and KICVentures Group CEO/Founder Kingsley R. Chin, M.D., is stepping down as CEO of NanoFuse Biologics. In August, KICVentures Group merged its holdings in NanoFUSE Biologics, InSpan and Sacrix into NANISX, a new spine company which will be divided into two ASC divisions. There is no word yet on Chin's replacement.
Lima Corporate, conversely, gained a new leader, appointing Massimo Calafiore as its new CEO. Emmanuel Bonhomme, who has been interim CEO for the last five months, will serve in the newly created role of chief commercial officer. Calafiore was most recently NuVasive’s executive vice president and chief commercial officer; prior that he led the company’s product marketing and commercial functions as well as business units NuVasive Specialized Orthopedics and NuVasive Clinical Services. Calafiore has more than 20 years of experience in the orthopedic field.
Stryker Corp. led digital clicks by launching its Pulse Intelligent Delivery Platfom, a a full-circle product and fulfillment offering optimized for high volume foot and ankle procedures in the ambulatory surgery center (ASC) setting. The company will debut the platform at this year’s American Orthopaedic Foot & Ankle Society Annual Meeting (AOFAS). The Pulse Intelligent Delivery Platform provides an integrated product configuration and delivery offering for foot and ankle surgery within the ASC setting of care through a suite of surgery-ready forefoot products designed to reduce clutter in the operating room as well as provide ease of use, sterilization processing cost savings, and sustainability; and radio frequency identification technology that monitors ASC inventory and triggers replenishment orders automatically.
Conformis followed close behind in traffic generation with the FDA 510(k) clearance of its Actera hip system, which adds a tri-taper femoral stem design to the company’s hip portfolio. Its design objective is to facilitate a minimally invasive approach similar to direct anterior, with easier femur access, less injury to muscles, and fewer potential nerve interactions.
Nanofuse Biologics and Lima Corporate, meanwhile, attracted cybervisitors with their respective personnel news. Board-certified orthopedic spine surgeon and KICVentures Group CEO/Founder Kingsley R. Chin, M.D., is stepping down as CEO of NanoFuse Biologics. In August, KICVentures Group merged its holdings in NanoFUSE Biologics, InSpan and Sacrix into NANISX, a new spine company which will be divided into two ASC divisions. There is no word yet on Chin's replacement.
Lima Corporate, conversely, gained a new leader, appointing Massimo Calafiore as its new CEO. Emmanuel Bonhomme, who has been interim CEO for the last five months, will serve in the newly created role of chief commercial officer. Calafiore was most recently NuVasive’s executive vice president and chief commercial officer; prior that he led the company’s product marketing and commercial functions as well as business units NuVasive Specialized Orthopedics and NuVasive Clinical Services. Calafiore has more than 20 years of experience in the orthopedic field.